Chantal Morel is a Research Officer within LSE Health. Her work is concentrated in the area of pharmaceutical policy, with focus on regulation and innovation. Her current projects explore the determinants of global pharmaceutical prices as well as intra- and extra-market-driven mechanisms to drive R&D in key areas of unmet medical need. Prior to joining the LSE Morel worked in health policy and economics as a Research Fellow at the London School of Hygiene & Tropical Medicine, as a Health Impact Assessment Adviser in a large INGO, and as a Health Economist within the guideline branch of the English national health authority.
Clift C, Gopinathan U, Morel CM, Outterson KO, Røttingen JA, and So A. (Eds) Towards a new Global Business Model for Antibiotics: Delinking Revenues from Sales. Report from the Chatham House Working Group on New Antibiotic Business Models. Publication forthcoming in July 2015.
Årdal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Smith R, Zorzet A, van de Sande N, Cohn J, Pittet D, Daulaire N, Morel CM, Rizvi Z , Røttingen JA. Effective international collaboration to improve access to and sustain effectiveness of antimicrobials. Accepted and forthcoming in Lancet 2015.
Morel CM, McClure L, Edwards SE, Goodfellow V, Sandberg D, Mossialos E. Ensuring innovation in diagnostics for bacterial infection: Implications for policy. Accepted and forthcoming in book format in 2015.
Morel CM & Edwards S. Addressing the urgent need for antibiotics in Europe. Policy Summary for the World Health Organization. 2014.
Morel CM, Thang ND, Erhart A, Xa NX, Peeters Grietens K, et al. Cost-Effectiveness of Long-Lasting Insecticide-Treated Hammocks in Preventing Malaria in South-Central Vietnam. PLoS ONE 2013 8(3).
Morel CM, McGuire A, Mossialos E. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Affairs 2011;30(8): 1545–1552.
White, A.R., Blaser, M., Carrs, O., Cassell, G., Fishman, N., Guidos, R., Levy, S., Powers, J., Norrby, R., Tillotson, G., Davies, R., Projan, S., Dawson, M., Monnet, D., Keogh-brown, M., Hand, K., Garner, S., Findlay, D., Morel, CM., Wise, R., Bax, R., Burke, F., Chopra, I., Czaplewski, L., Finch, R., Livermore, D., Piddock, L.J.V., White, T.Effective antibacterials: At what cost? The economics of antibacterial resistance and its control. Journal of Antimicrobial Chemotherapy volume 66, issue 9, year 2011, pp. 1948 – 1953
Wise R, Blaser M, Cars O, Cassell G, Fishman N, Guidos R, Levy S, Powers J, Norrby R, Tillotson G, Davies R, Projan S, Dawson M, Monnet D, Keogh-Brown M, Hand K, Garner S, Findlay D, Morel CM, Bax R, Burke F, Chopra I, Czaplewski L, Finch R, Livermore D, Piddock LJV, White T. (Working Group of the British Society of Antimicrobial Chemotherapy) The urgent need for new antibacterial agents. Journal of Antimicrobial Chemotherapy 2011; 66: 1939-1940.
Livermore D, Wise R, Blaser M, Cars O, Cassell G, Fishman N, Guidos R, Levy S, Powers J, Norrby R, Tillotson G, Davies R, Projan S, Dawson M, Monnet D, Keogh-Brown M, Hand K, Garner S, Findlay D, Morel CM, Bax R, Burke F, Chopra I, Czaplewski L, Finch R, Piddock LJV, White T. (Working Group of the British Society of Antimicrobial Chemotherapy) Discovery research: the scientiﬁc challenge of ﬁnding new antibiotics. Journal of Antimicrobial Chemotherapy 2011; 66: 1941–1944.
Morel CM, Mossialos E. Stoking the antibiotic pipeline. British Medical Journal 2010; 340:1115-1118.
Mossialos E, Morel CM, Edwards SE, Berensen J, Gemmill-Toyama M, Brogen D. Policies and Incentives for promoting innovation in antibiotic research. 2010 Book published by the WHO Observatory on Health Systems and Policies.
Reidpath D, Morel CM, Mecaskey J, Allotey P. The Millennium Development Goals fail poor children: the case for equity-adjusted measures. PLoS Medicine 2009 ;6(4).
Morel CM, Ngo Duc T, Nguyen X, Pham Van K, Le Xuan H, Le Khan T, Erhart A, Mills AJ, D’Alessandro U. The economic burden of malaria on the household in south-central Vietnam. Malaria Journal 2008, 7:166.
Shillcutt S, Morel CM, Goodman C, Coleman PC, Bell D, Whitty CJM, Mills AJ. The cost-effectiveness of malaria diagnostic methods in an era of artemisinin-based combination therapy. Bulletin of the World Health Organization 2008 Feb;86(2):101-10.
Worrall E, Morel CM, Yeung S, Borghi J, Webster J, Hill J, Wiseman V, Mills A. The economics of malaria in pregnancy—a review of the evidence and research priorities, Lancet Infectious Diseases 2007; 7:156-168.
Breman J, Mills A, Snow R, Mulligan J, Mendis K, Sharp B, Steketee R, White N, Doumbo O. Lengeler C, Morel CM, and Marchesini P; Conquering Malaria in 'Disease Control Priorities in Developing Countries' Jamison D; Breman J; Measham A; Alleyne G; Claeson, M; Evans, D; Jha, P; Mills, A; Musgrove, P (eds) World Bank and OUP 2006.
Morel CM, Lauer J, Evans D. Cost-effectiveness analysis for the MDGs for health: a reassessment of current strategies in malaria control, British Medical Journal 2005; 331(7528):1299.
Coleman PC, Morel CM, Shillcutt S, Goodman C, Mill AJ. A threshold analysis of the cost-effectiveness of artemisinin-based combination therapies in sub-Saharan Africa, American Journal of Tropical Medicine & Hygiene, 2004; 71 (2 Suppl):196-204.
Saving Lives, Buying Time, chapter in book (contribution as part of the Committee on the Economics of Antimalarial Drugs) Arrow K, Panosian C, and Gelband H (Eds) Institute of Medicine of the National Academies 2004.
Coleman P, Goodman C, Mills AJ, Morel CM, Shillcutt S, Yeung S. When is confirmed malaria diagnosis cost-effective? British Medical Journal, 2004; 328:1511-1512
Mulligan J & Morel CM. The Cost of Policy Change: System Strengthening and Implementation prior to a change in malaria drug policy, operational strategy report 2004, report for United States Agency for International Development
For a full list of Chantal's publications, please see her LSE Research Online page